{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:43:12Z","timestamp":1790772192868,"version":"4.1.0"},"reference-count":10,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,4]]},"DOI":"10.1182\/blood.2023023576","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T15:30:50Z","timestamp":1712244650000},"page":"1317-1318","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["A treatment bridge for infants with hemophilia"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-7358","authenticated-orcid":false,"given":"Thomas C.","family":"Abshire","sequence":"first","affiliation":[{"name":"Versiti Blood Research Institute and Medical College of Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2024040415304576300_bib1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"issue":"26","key":"2024040415304576300_bib2","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood.2021011849","article-title":"Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis","volume":"138","author":"Zwagemaker","year":"2021","journal-title":"Blood"},{"issue":"20","key":"2024040415304576300_bib3","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2024040415304576300_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024040415304576300_bib5","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024040415304576300_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients with hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2024040415304576300_bib7","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without\u00a0FVIII inhibitors from the HAVEN 1-4\u00a0studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"suppl 6","key":"2024040415304576300_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"2024040415304576300_bib9","unstructured":"National Hemophilia Association\n          . MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra\u00ae) for hemophilia A with and without inhibitors. MASAC Document #258. Accessed 27 November 2023. https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/258_emicizumab.pdf."},{"issue":"3","key":"2024040415304576300_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia\u00a0A\u00a0with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemostasis"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/14\/1317\/2219789\/blood_bld-2023-023576-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/14\/1317\/2219789\/blood_bld-2023-023576-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T15:30:58Z","timestamp":1712244658000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/14\/1317\/515485\/A-treatment-bridge-for-infants-with-hemophilia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":10,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,4,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023576","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}